Siddiqui U Prevalence and predictors of herbal medication use in veterans with chronic hepatitis C. J Clin
Gastroenterol. 2004 Aug;38(7):605-10.  Wallace SN Extraction of nutraceuticals from milk thistle: part II. Extraction
with organic solvents. Appl Biochem Biotechnol. 2003 Spring;105 -108:891-903.  Wallace SN Batch solvent
extraction of flavanolignans from milk thistle (Silybum marianum L. Gaertner). Phytochem Anal. 2005
Jan-Feb;16(1):7-16. Duan L Silymarin extraction from milk thistle using hot water. Appl Biochem Biotechnol. 2004
Spring;113-116:559-68. Lee DY, Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and
isosilybin B, Isolated from Silybum marianum (milk thistle). J Nat Prod. 2003 Dec;66(12):1632.  Kim NC Complete
isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem.
2003 May 21;1(10):1684-9. Manna SK Silymarin [MILK THISTLE] suppresses TNF-induced activation of NF-kappa
B, c-Jun N-terminal kinase, and apoptosis. J Immunol. 1999 Dec 15;163(12):6800-9.  Lee DG et al Gram-positive
bacteria specific properties of silybin derived from Silybum marianum [Milk Thistle]. Arch Pharm Res. 2003
Aug;26(8):597-600. Soliman KF In vitro attenuation of nitric oxide production in C6 astrocyte cell culture by
various dietary compounds. Proc Soc Exp Biol Med. 1998 Sep;218(4):390-7. Bialecka M. The effect of
bioflavonoids and lecithin on the course of experimental atherosclerosis in rabbits Ann Acad Med Stetin.
1997;43:41-56. Zi X, Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin [MILK THISTLE]:
inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun. 1997
Oct 9;239(1):334-9.Tyagi A Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell
carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis.
2004 Sep;25(9):1711-20. Epub 2004 Apr *milk thistle Tyagi AK Silibinin down-regulates survivin protein and
mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4
cells. Biochem Biophys Res Commun. 2003 Dec 26;312(4):1178-84. Vinh PQ et al Chemopreventive effects of a
flavonoid antioxidant silymarin [MILK THISTLE] on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder
carcinogenesis in male ICR mice. Jpn J Cancer Res. 2002 Jan;93(1):42-9. Tyagi AK Synergistic anti-cancer
effects of silibinin [milk thistle extract] with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin
against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 2004 Feb;11(2):493-9.Zi X.
Anticarcinogenic effect of a flavonoid antioxidant, silymarin [milk thistle], in human breast cancer cells MDA-MB 468:
induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of
cyclin-dependent kinases and associated cyclins. Clin Cancer Res. 1998 Apr;4(4):1055-64. Kohno H et al,
Silymarin [MILK THISTLE], a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced
colon carcinogenesis in male F344 rats. Int J Cancer. 2002 Oct 10;101(5):461-8. Yoo HG Involvement of
NF-kappaB and caspases in silibinin-induced apoptosis of endothelial cells. Int J Mol Med. 2004 Jan;13(1):81-6.
Qi L, Epidermal growth factor receptor mediates silibinin [milk thistle]-induced cytotoxicity in a rat glioma cell line.
Cancer Biol Ther. 2003 Sep-Oct;2(5):526-31. Chu SC Silibinin inhibits the invasion of human lung cancer cells
via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog. 2004
Jul;40(3):143-9. Ladas EJ Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? J
Altern Complement Med. 2003 Jun;9(3):411-6. [Davis-Searles PR, Milk thistle and prostate cancer: differential
effects of pure flavonolignans from Silybum marianum [MILK THISTLE] on antiproliferative end points in human
prostate carcinoma cells. Cancer Res. 2005 May 15;65(10):4448-57]  Singh RP A cancer chemopreventive
agent silibinin [MILK THISTLE], targets mitogenic and survival signaling in prostate cancer. Mutat Res. 2004 Nov
2;555(1-2):21-32. Thelen P Silibinin down-regulates prostate epithelium-derived Ets transcription factor in
LNCaP prostate cancer cells. Planta Med. 2004 May;70(5):397-400. Inhibition of telomerase activity and
secretion of prostate specific antigen by silibinin [milk thistle] in prostate cancer cells. J Urol. 2004
May;171(5):1934-8.  Prostate cancer prevention by silibinin [milk thistle]. Curr Cancer Drug Targets. 2004
Feb;4(1):1-11  A flavonoid antioxidant, silymarin [milk thistle], inhibits activation of erbB1 signaling and induces
cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145
cells. Cancer Res. 1998 May 1;58(9):1920-9. 27 Silibinin [Milk Thistle] decreases prostate-specific antigen with cell
growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer
intervention. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7490-5. 28 Dhanalakshmi S Silibinin [MILK THISTLE]
sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and
apoptotic death. Int J Cancer. 2003 Sep 20;106(5):699-705. 29 Zi X Silibinin [MILK THISTLE] up-regulates
insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate
cancer cells Cancer Res. 2000 Oct 15;60(20):5617-20.  Singh RP Dietary feeding of [MILK THISTLE] silibinin
inhibits advance human prostate carcinoma growth in athymic mice and increases plasma insulin-like growth
factor-binding protein-3 levels. Cancer Res. 2002 Jun 1;62(11):3063-9. Tyagi A et al, Silibinin [MILK THISTLE]
strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest,
and apoptosis. Clin Cancer Res. 2002 Nov;8(11):3512-9.  Tyagi A Antiproliferative and apoptotic effects of
silibinin [MILK THISTLE] in rat prostate cancer cells. Prostate. 2002 Nov 1;53(3):211-7.Katiyar SK et al,
Protective effects of silymarin [milk thistle] against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst.
1997 Apr 16;89(8):556-66] Katiyar SK. Silymarin [milk thistle] and skin cancer prevention: anti-inflammatory,
antioxidant and immunomodulatory effects (Review). Int J Oncol. 2005 Jan;26(1):169-76. Silibinin prevents
ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and
an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis. 2004 Aug;25(8):1459-65. Epub 2004 Mar 19. A
flavonoid antioxidant, silymarin [milk thistle], affords exceptionally high protection against tumor promotion in the
SENCAR mouse skin tumorigenesis model. Cancer Res. 1999 Feb 1;59(3):622-32 Yanaida Y et al Dietary
silymarin [MILK THISTLE] suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats.
Carcinogenesis. 2002 May;23(5):787-94.Silymarin [Milk thistle]: potent inhibitor of cyclic AMP
phosphodiesterase. Methods Find Exp Clin Pharmacol. 1985 Aug;7(8):409-13.]Crocenzi FA et al, Silibinin [Milk
thistle] prevents cholestasis-associated retrieval of the bile salt export pump, Bsep, in isolated rat hepatocyte
couplets: possible involvement of cAMP. Biochem Pharmacol. 2005 Apr 1;69(7):1113-20.]
 von Schonfeld J Silibinin [Milk thistle], a plant extract with antioxidant and membrane stabilizing properties,
protects exocrine pancreas from cyclosporin A toxicity. Cell Mol Life Sci. 1997 Dec;53(11-12):917-20.]  Maghrani
M Study of the hypoglycaemic activity of Fraxinus excelsior and Silybum marianum [Milk thistle] in an animal model
of type 1 diabetes mellitus. J Ethnopharmacol. 2004 Apr;91(2-3):309-16.  Chlopcikova S Chemoprotective effect
of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin [Milk thistle] and its
flavonolignans. Phytother Res. 2004 Feb;18(2):107-10.  Katiyar SK. Treatment of silymarin [MILK THISTLE], a
plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J
Oncol. 2002 Dec;21(6):1213-22. Wilasrusmee C et al, Immunostimulatory effect of Silybum Marianum (milk
thistle) extract. Med Sci Monit. 2002 Nov;8(11):BR439-43. Ferenci P et al, Randomized controlled trial of
silymarin [Milk thistle] treatment in patients with cirrhosis of the liver. J Hepatol. 1989 Jul;9(1):105-13.  Arteel G
Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol. 2003 Aug;17(4):625-47. Lieber CS
Silymarin [Milk thistle] retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol.
2003 Oct;37(4):336-9.. Dehmlow C. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective
properties of silibinin. Hepatology. 1996 Apr; 23 (4): 749-54. . Wu DF The effects of silymarin [Milk thistle] on
hepatic microsomal and mitochondrial membrane fluidity in mice. Zhongguo Zhong Yao Za Zhi. 2003
Sep;28(9):870-2.  Tanamly MD et al, Randomised double-blinded trial evaluating silymarin [Milk thistle] for
chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004
Nov;36(11):752-9. Tedesco D Silymarin, a possible hepatoprotector in dairy cows: biochemical and histological
observations. J Vet Med A Physiol Pathol Clin Med. 2004 Mar;51(2):85-9. Wang MJ Silymarin [MILK THISTLE]
protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation.
Eur J Neurosci. 2002 Dec;16(11):2103-12  Kittur S et al, Neurotrophic and neuroprotective effects of milk thistle
(Silybum marianum) on neurons in culture. J Mol Neurosci. 2002 Jun;18(3):265-9.
 Hu Z, Herb-drug interactions: a literature review. Drugs. 2005;65(9):1239-82.]DiCenzo R Coadministration
of milk thistle and indinavir in healthy subjects. Pharmacotherapy. 2003 Jul;23(7):866-70. Giese LA. Milk thistle
and the treatment of hepatitis. Gastroenterol Nurs. 2001 Mar-Apr;24(2):95-7.  Saller R et al, The use of silymarin
in the treatment of liver diseases Drugs. 2001;61(14):2035-63. Ferenci P. et al, Randomized controlled trial of
silymarin (milk thistle) treatment in patients with cirrhosis of the liver. J Hepatol. 1989 Jul;9(1):105-13. Silymarin
inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Med. 2003
Jan;69(1):44-9. Jacobs BP, Milk thistle for the treatment of liver disease: a systematic review and meta-analysis.
Am J Med. 2002 Oct 15;113(6):506-15. Rambaldi A. et al, Milk thistle for alcoholic and/or hepatitis B or C virus
liver diseases. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003620.] Physiological responses of a natural
antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but
stimulates inflammatory processes at high doses. Planta Med. 2003 Jan;69(1):44-9.
[aa1] Raza SS, t al, Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia:
a behavioral, biochemical and immunohistological study in Wistar rats. J Neurol Sci. 2011 Oct 15;309(1-2):45-54.
[aa2] Suksomboon N et al, Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J
Ethnopharmacol. 2011 Aug 5 [aa3] Kim JL,et al, Osteoblastogenesis and osteoprotection enhanced by
flavonolignan silibinin in osteoblasts and osteoclasts.J Cell Biochem. 2011 Sep 6 [aa4] Lian R, et al, Silymarin
Glyceryl Monooleate/Poloxamer 407 Liquid Crystalline Matrices: Physical Characterization and Enhanced Oral
Bioavailability. AAPS PharmSciTech. 2011 Sep 23.
|Milk Thistle Reference
October 18, 2011